- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02370173
A Non-Pharmacological Method for Enhancing Sleep in PTSD
Sleep disturbance is nearly ubiquitous among individuals suffering from PTSD and is a major problem among service members returning from combat deployments. The proposed study aims to test a novel, inexpensive, and easy to use approach to improving sleep among service members with PTSD.
Primary outcome measures will include not only PTSD symptom improvement but also include neuroimaging of brain structure, function, connectivity, and neurochemistry changes. The proposal is firmly grounded in the emerging scientific literature regarding sleep, light exposure, brain function, anxiety, and resilience. Prior evidence suggests that bright light therapy is effective for improving mood and fatigue, and our pilot data further suggest that this treatment may be effective for improving daytime sleepiness and brain functioning in brain injured individuals. Thus, this intervention, in our own research and in the work of others, has been shown to affect critical sleep regulatory systems. Improving sleep may be a vital component of recovery in these service members. Our approach would directly address this issue. Our preliminary data have shown that this approach is extremely well tolerated and is effective for improving sleep, mood, cognitive performance, and brain function among individuals with brain injuries.
Finally, the potential impact of this study is high because of the capability of transitioning the research to direct clinical application almost immediately. If the bright light treatment is demonstrated as effective, this approach would be readily available for nearly immediate large-scale implementation, as the devices have been widely used for years in other contexts, are already safety tested, and commercially available from several manufacturers for a very low cost. Thus, the impact of this research on treating PTSD would be high and immediate.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Arizona
-
Tucson, Arizona, United States, 85724
- University of Arizona Psychiatry Department
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
- Having experienced a traumatic event within the past 10 years
- Right handedness
- 18-50 years old
- Primary language is English
- No metal in body
Further eligibility will be determined through a phone screening. Please call (520) 626-8591 or go to uascanlab.com to check your eligibility for this study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PTSD wavelength-1 bright light
30 minutes of daily light exposure for 6 weeks
|
6 weeks of daily light exposure, 30 minutes per morning.
|
Placebo Comparator: PTSD wavelength-2 bright light
30 minutes of daily light exposure for 6 weeks
|
6 weeks daily light exposure, 30 minutes per morning.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep Efficiency
Time Frame: Sleep Efficiency was calculated at Baseline (Pre-Treatment) and Post-Treatment (6 Weeks after Baseline)
|
Actigraphy was used as a measurement of individual sleep efficiency calculating total sleep time (minutes asleep) divided by total rest time (time in bed- minutes in bed).
This produces a percentage efficiency calculation that can range 0-100%, higher percentages indicates more time asleep while in bed.
|
Sleep Efficiency was calculated at Baseline (Pre-Treatment) and Post-Treatment (6 Weeks after Baseline)
|
Subjective Sleep Quality
Time Frame: Results 6 weeks post-treatment
|
Pittsburgh Sleep Quality Index is a measurement of subjective self-report sleep quality that uses both free response and Likert scale responses.
The range of scores possible are 0 to 21.
Higher scores indicate worse subjective sleep quality.
|
Results 6 weeks post-treatment
|
Neural Activation During Functional Magnetic Resonance Imaging (fMRI) Emotion Processing Task
Time Frame: Baseline (Pre-Treatment) and Post-Treatment (6 Weeks after Baseline)
|
Activation of medial prefrontal cortex and anterior cingulate cortex (also prefrontal) during functional magnetic resonance imaging (fMRI) Backward Masked Affect Task (BMAT) emotion processing task.
Contrast weight/effect scores for prefrontal area [MNI coordinates: 18,42,12] measured contrasts in activation between neutral images and activation when emotional images (fear images) were presented during the task.
Higher scores indicate a greater difference or contrast between the neutral signal and emotional signal during the fMRI task.
|
Baseline (Pre-Treatment) and Post-Treatment (6 Weeks after Baseline)
|
Performance on Neuropsychological Assessment
Time Frame: Performance results at 6 weeks post-treatment.
|
The Repeatable Battery for the Assessment of Neuropsychological Status will be utilized to measure overall neurocognitive performance.
It covers five domains of cognition: Immediate Memory, Visuospatial/Constructional, Language, Attention, and Delayed Memory resulting in a total neurocognitive performance score.
The range of overall total neurocognitive performance scores is 40-160 points.
Higher scores on this scale represent a higher capacity for executive function.
|
Performance results at 6 weeks post-treatment.
|
PTSD Symptoms
Time Frame: Performance results at 6 weeks post-treatment.
|
Post Traumatic Stress Disorder Checklist 5 (PCL-5).The PTSD Checklist for DSM-5 is a 20-item self-report measure that assesses the presence and severity of PTSD symptoms.
Items are summed to provide a total severity score (range = 0-80).
Higher scores indicate greater presence or severity of PTSD symptoms.
|
Performance results at 6 weeks post-treatment.
|
Daytime Sleepiness (ESS)
Time Frame: Performance results at 6 weeks post-treatment
|
Epworth Sleepiness Scale is a subjective measure of daytime sleepiness.
This is on a 4-point Likert scale, each item has a range of 0 to 3 points.
The total score range for this is 0-24 points.
Higher scores indicate more severe daytime sleepiness.
|
Performance results at 6 weeks post-treatment
|
Daytime Sleepiness (SSS)
Time Frame: Performance results at 6 weeks post-treatment.
|
Stanford Sleepiness Scale is a one item scale assessing current level of alertness.
The range of points possible is 1-7, with higher scores indicating that sleep onset is soon.
This scale was given at three different time points during baseline assessment and post treatment.
|
Performance results at 6 weeks post-treatment.
|
Daytime Sleepiness (MSLT)
Time Frame: Change from baseline performance at 6 weeks (post-treatment)
|
Multiple Sleep Latency Test (MSLT).
Participants were administered a modified Multiple Sleep Latency Test.
In the multiple sleep latency test (MSLT), the participant was given 3 opportunities to nap for 20 minutes every two hours.
Sleep latency scores are calculated in the number of seconds to fall asleep during their mandated sleep session.
Range is from 0 seconds to 1200 seconds.
|
Change from baseline performance at 6 weeks (post-treatment)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: William Killgore, Ph.D., University of Arizona
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1407389306A003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on PTSD
-
University of PittsburghCompletedPTSD | Non PTSDUnited States
-
Imperial College Healthcare NHS TrustImperial College LondonRecruiting
-
VA Office of Research and DevelopmentUniversity of California, San DiegoRecruiting
-
University of Wisconsin, MadisonNational Institute of Mental Health (NIMH)Active, not recruiting
-
Oregon Health and Science UniversityEnrolling by invitation
-
VA Office of Research and DevelopmentCompleted
-
VA Office of Research and DevelopmentPortland VA Medical CenterActive, not recruiting
-
VA Office of Research and DevelopmentSan Diego Veterans Healthcare SystemCompleted
-
Creighton UniversityCompleted
-
VA Eastern KansasTerminated
Clinical Trials on PTSD wavelength-1 bright light
-
University of ArizonaU.S. Army Medical Research Acquisition ActivityCompletedConcussion, Mild | Sleep Problems | Post-Concussion SymptomsUnited States
-
University of ArizonaU.S. Army Medical Research Acquisition ActivityCompletedConcussion, Mild | Sleep Problems | Post-Concussion SymptomsUnited States
-
China Medical University HospitalNot yet recruiting
-
Shanghai Eye Disease Prevention and Treatment CenterRecruiting
-
Yale UniversityCompletedCircadian Rhythm Sleep Disorder, UnspecifiedUnited States
-
University of BergenCompleted
-
Radford UniversityCommonwealth Care of Roanoke, Inc.; Virginia Center on Aging (ARDRAF)Completed
-
ToeFX Inc.Active, not recruiting
-
Shanghai Zhongshan HospitalFudan University; Shanghai Mental Health Center, Jingan District; Shanghai Mental...Unknown
-
Northwestern UniversityRush UniversityCompletedPreDiabetes | Circadian DysregulationUnited States